ACRX - AcelRx Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5171.64M
Enterprise Value 397.86M
Trailing P/E N/A
Forward P/E 1-3.30
PEG Ratio (5 yr expected) 1N/A
Price/Sales (ttm)82.80
Price/Book (mrq)N/A
Enterprise Value/Revenue 347.21
Enterprise Value/EBITDA 6-2.51

Trading Information

Stock Price History

Beta (3Y Monthly) 2.31
52-Week Change 3-43.12%
S&P500 52-Week Change 37.14%
52 Week High 35.0500
52 Week Low 31.9900
50-Day Moving Average 32.6831
200-Day Moving Average 32.9307

Share Statistics

Avg Vol (3 month) 31.45M
Avg Vol (10 day) 31.01M
Shares Outstanding 578.91M
Float 77.85M
% Held by Insiders 111.62%
% Held by Institutions 119.73%
Shares Short (Jun 14, 2019) 413.69M
Short Ratio (Jun 14, 2019) 410.71
Short % of Float (Jun 14, 2019) 417.63%
Short % of Shares Outstanding (Jun 14, 2019) 417.35%
Shares Short (prior month May 15, 2019) 413.58M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Mar 31, 2019

Profitability

Profit Margin 0.00%
Operating Margin (ttm)-1,918.77%

Management Effectiveness

Return on Assets (ttm)-27.74%
Return on Equity (ttm)N/A

Income Statement

Revenue (ttm)2.07M
Revenue Per Share (ttm)0.03
Quarterly Revenue Growth (yoy)-22.70%
Gross Profit (ttm)-14.96M
EBITDA -39.02M
Net Income Avi to Common (ttm)-49.23M
Diluted EPS (ttm)-0.7560
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)90.15M
Total Cash Per Share (mrq)1.14
Total Debt (mrq)15.18M
Total Debt/Equity (mrq)N/A
Current Ratio (mrq)5.03
Book Value Per Share (mrq)-0.10

Cash Flow Statement

Operating Cash Flow (ttm)-34.94M
Levered Free Cash Flow (ttm)-26.96M